GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRX-010 overview
IRX-010 is under development for the treatment of inflammatory disease. It is administered through intravenous route.
ImmunoRx Pharma overview
ImmunoRx Pharma a company that plans to develop a first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. It is headquartered in Wilmington, Delaware, the US.
For a complete picture of IRX-010’s drug-specific PTSR and LoA scores, buy the report here.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.